Release Date: 18 December 2025
Orphan drugs, also known as rare drugs, have steadily emerged as an innovative segment in the pharmaceutical industry of the US. These drugs target diseases that affect fewer than 200,000 people across the US, and hence l...
Release Date: 14 September 2025
Breast cancer remains one of the most prevalent malignancies worldwide, and despite progress with hormone therapies, chemotherapy, and targeted biologics, resistance and relapse continue to ...
Release Date: 14 September 2025
Bicycle toxin conjugates (BTCs) are an emerging therapeutic modality that combines the precision of targeted therapy with the potent cytotoxicity of payload delivery. Unlike traditional anti...
Release Date: 14 September 2025
Peptide cancer vaccines are gaining momentum as one of the most relevant innovations in modern oncology. Unlike conventional treatments such as chemotherapy and radiation, which broadly targe...
Release Date: 12 July 2025
The US orphan drug market has transformed into a cornerstone of innovation, delivering life-changing therapies for patients with rare diseases who historically lacked effective treatment options. This transformation was i...
Release Date: 11 July 2025
The rising prominence of bispecific antibodies marks a transformative shift in therapeutic modalities. These engineered molecules, designed to engage two distinct targets simultaneously, offer unprecedented precision in t...
Release Date: 11 July 2025
The FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) in early July 2025, for the treatment of adults with relapsed or refractory multiple myeloma (MM), after its prior conditional approval by the Europea...
Release Date: 10 July 2025
KIF18A Targeting Therapies represent an emerging frontier in cancer treatment, promising a precision based approach for malignancies characterized by chromosomal instability (CIN). KIF18A, or Kinesin Family Member 18A, pl...
Release Date: 09 July 2025
The US market for orphan drugs has been growing spectacularly since 1983, when the Orphan Drug Act (ODA), a landmark policy aimed at encouraging therapy development for rare diseases, i.e., those that afflict fewer than 2...
Release Date: 19 June 2025
CD5 targeting therapies are emerging as an innovative approach in cancer immunotherapy, providing new avenues to harness the immune system’s potential against malignancies. CD5, primarily known as a surface receptor...
Release Date: 17 June 2025
Chimeric Antigen Receptor T-cell (CAR-T) therapies have revolutionized cancer treatment, particularly for hematologic malignancies. A novel and promising approach involves targeting CD5, a protein predominantly expressed on T cells. While CD5 is crit...
Release Date: 30 May 2025
The global TROP2-targeting therapy market is transforming quickly, driven by growing interest in this transmembrane glycoprotein as a singular target in solid tumors. With more than 40 therapies under development and thre...
Release Date: 29 May 2025
Peptide cancer therapeutics has swiftly become a prominent approach in oncology, offering precise targeting capabilities alongside reduced side effects compared to traditional chemotherapies. Clinically, peptides represen...
Release Date: 28 May 2025
The US orphan drugs market is a compelling success story of pharmaceutical innovation, turning long-ignored therapeutic areas into a lucrative industry worth around US$ 100 billion as of 2024. The niche market segment has...
Release Date: 28 May 2025
The global multispecific antibodies immunotherapy market is a paradigm-breaking cancer treatment, leveraging the host immune system using advanced molecular engineering that facilitates simultaneous action on several path...